Regeneration of pancreatic islets by amniotic fluid stem cell therapy
A method of treating diabetes in a mammalian subject is carried out by: (a) providing mammalian amniotic fluid stem cells, and then (b) administering the cells to the subject in an amount effective to treat diabetes. Optionally, the cells may be differentiated into pancreatic-like cells or at least treated to initiate subsequent differentiation into-pancreatic-like cells, prior to administration.
1. A method of treating insulin-dependent diabetes in a human subject in need thereof, comprising the steps of:
(i) providing a pharmaceutical composition comprising human amniotic fluid-derived stem cells, wherein said amniotic fluid-derived stem cells:
(a) specifically bind c-kit antibodies at the time of collection,
(b) are transfected with a nucleic acid expressing Pdx-1,
(c) express the cell surface marker CD44 and do not express CD34 and CD105 cell surface markers, and
(ii) administering the pharmaceutical composition of step (i) to said human subject in an amount effective to treat said insulin-dependent diabetes.
2. The method of claim 1 , wherein said human amniotic fluid-derived stem cells:
(a) proliferate through at least 200 population doublings when grown in vitro,
(b) do not require feeder cell layers to grow in vitro, and
(c) do not form teratomas when grown in vivo.
3. The method of claim 1 , wherein said administering step is carried out by intraveneous or intraarterial injection.
4. The method of claim 1 , wherein said cells are administered in an amount of from about 1×10 5 to about 1×10 9 cells per subject.
5. The method of claim 1 , wherein said subject is effectively treated for said diabetes for at least two months after said administering step.
6. The method of claim 1 , wherein said cells are not differentiated into pancreatic-like cells prior to said administering step.
7. The method of claim 1 , wherein said cells are encapsulated in an insulin-permeable capsule.
8. The method of claim 1 , wherein said cells are unencapsulated.
9. The method of claim 1 , wherein said subject is an adult subject.
10. The method of claim 1 , wherein said subject is an adolescent subject.
11. The method of claim 1 , wherein said subject is a juvenile subject.
12. The method of claim 1 , wherein said providing in step (i) is carried out by collecting amniotic fluid-derived stem cells from a human donor, and then expanding said human amniotic fluid-derived stem cells in vitro.
13. A pharmaceutical composition for the treatment of diabetes comprising amniotic fluid-derived stem cells, wherein said amniotic fluid-derived stem cells:
(i) specifically bind c-kit antibodies at the time of collection,
(ii) are transfected with a nucleic acid expressing Pdx-1,
(iii) express the cell surface marker CD44 and do not express CD34 and CD105 cell surface markers, and
(iv) are provided in a treatment-effective amount.
14. The composition of claim 13 , wherein said composition comprises an aqueous carrier.
15. The composition of claim 13 in unit dosage form.
16. The composition of claim 13 , wherein said composition is an injectable composition.
17. The composition of claim 13 , wherein said amniotic fluid-derived stem cells are encapsulated in an insulin-permeable capsule.
18. The composition of claim 13 , wherein said amniotic fluid-derived stem cells are unencapsulated.
19. The composition of claim 13 , wherein said amniotic fluid-derived stem cells are human cells.
20. The composition of claim 13 , wherein said amniotic fluid-derived stem cells:
(i) are collected from amniotic fluid of a mammalian donor,
(ii) differentiate upon appropriate stimulation into at least osteogenic, adipogenic, myogenic, neurogenic, hematopoietic, and endothelial cell lines,
(iii) proliferate through at least 200 population doublings when grown in vitro,
(iv) do not require feeder cell layers to grow in vitro, and
(v) do not form teratomas when grown in vivo.
21. The composition of claim 13 , wherein said amniotic fluid-derived stem cells express the transcription factor Oct-4, SSEA-1, Sca-1, and CD90.
22. The composition of claim 13 , wherein said nucleic acid comprises DNA or RNA.
23. The composition of claim 13 , wherein said nucleic acid is RNA.
24. The composition of claim 13 , wherein said composition is isotonic with human blood.
25. The composition of claim 13 , wherein said composition comprises from about 1×10 5 to about 1×10 9 of said cells.
26. The composition of claim 14 , wherein said cells are provided as a suspension in the carrier.
27. A pharmaceutical composition for the treatment of diabetes comprising amniotic fluid-derived stem cells transfected with a nucleic acid expressing Pdx-1, wherein said amniotic fluid-derived stem cells:
(i) are collected from amniotic fluid of a mammalian donor,
(ii) proliferate through at least 200 population doublings when grown in vitro,
(iii) do not require feeder cell layers to grow in vitro,
(iv) do not form teratomas when grown in vivo,
(v) specifically bind c-kit antibodies at the time of collection,
(vi) express the cell surface marker CD44 and do not express CD34 and CD 105 cell surface markers, and
(vii) are provided in a treatment-effective amount,
wherein said composition is an injectable composition that is isotonic with human blood.
28. The composition of claim 27 , wherein said amniotic fluid-derived stem cells are human cells.
29. The composition of claim 27 , wherein said nucleic acid comprises DNA or RNA.
30. The composition of claim 27 , wherein said nucleic acid is RNA.
31. The composition of claim 27 , wherein said composition comprises from about 1×10 5 to about 1×10 9 of said cells.
32. The composition of claim 27 , wherein said cells are provided as a suspension in a carrier.